SOCM
ORKA

SR One Capital Management’s Oruka Therapeutics ORKA Stock Holding History

SR One Capital Management’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-430,330
Closed -$21.1M – 17
2026
Q1 		$21.1M Hold
430,330
– – 2.31% 10
2025
Q4 		$13M Hold
430,330
– – 1.85% 9
2025
Q3 		$8.28M Hold
430,330
– – 1.2% 8
2025
Q2 		$4.82M Hold
430,330
– – 1.05% 11
2025
Q1 		$4.42M Hold
430,330
– – 1.13% 10
2024
Q4 		$8.34M Buy
430,330
+55,000
+15% +$1.34M 2.03% 8
2024
Q3 		$9.2M Buy
+375,330
New +$13.1M 1.84% 9

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

SR One Capital Management's ORKA Position: Q2 2026 in Review

SR One Capital Management sold out of Oruka Therapeutics (ORKA) in Q2 2026, closing a stake of 430,330 shares — an estimated $21.1M sold.

SR One Capital Management first reported a position in ORKA in Q3 2024 and held it in 7 quarters. The position peaked at $21.1M in Q1 2026. 255 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

  • SR One Capital Management reported no remaining Oruka Therapeutics position as of Q2 2026 after selling out during the quarter.
  • SR One Capital Management sold 430,330 Oruka Therapeutics shares in Q2 2026, an estimated $21.1M.
  • SR One Capital Management first reported a position in Oruka Therapeutics in Q3 2024 and held it in 7 quarters.
  • SR One Capital Management's Oruka Therapeutics position peaked at $21.1M in Q1 2026.
  • 255 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on SR One Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.